督脉针刺治疗缺血性中风后运动功能障碍解释性随机对照试验

注册号:

Registration number:

ITMCTR2025001316

最近更新日期:

Date of Last Refreshed on:

2025-07-01

注册时间:

Date of Registration:

2025-07-01

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

督脉针刺治疗缺血性中风后运动功能障碍解释性随机对照试验

Public title:

Interpretative randomised controlled trial of governor vein acupuncture in the treatment of motor dysfunction after ischemic stroke

注册题目简写:

English Acronym:

研究课题的正式科学名称:

督脉针刺治疗缺血性中风后运动功能障碍解释性随机对照试验

Scientific title:

Interpretative randomised controlled trial of governor vein acupuncture in the treatment of motor dysfunction after ischemic stroke

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

曹馨元

研究负责人:

尹洪娜

Applicant:

xinyuancao

Study leader:

hongnayin

申请注册联系人电话:

Applicant telephone:

18846925047

研究负责人电话:

Study leader's telephone:

13101581588

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cxy18846925047@163.com

研究负责人电子邮件:

Study leader's E-mail:

hljtcmacu@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

黑龙江省中医药大学

研究负责人通讯地址:

黑龙江省中医药大学附属第二医院

Applicant address:

Heilongjiang University of Chinese Medicine

Study leader's address:

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

黑龙江省中医药大学

Applicant's institution:

Heilongjiang University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

IRB-AF/SG-20/04.0

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

黑龙江中医药大学附属第二医院

Name of the ethic committee:

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/1/10 0:00:00

伦理委员会联系人:

林春盛

Contact Name of the ethic committee:

chunshenglin

伦理委员会联系地址:

黑龙江中医药大学附属第二医院

Contact Address of the ethic committee:

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine

伦理委员会联系人电话:

Contact phone of the ethic committee:

0451-53628834

伦理委员会联系人邮箱:

Contact email of the ethic committee:

529961612@qq.com

研究实施负责(组长)单位:

黑龙江中医药大学附属第二医院

Primary sponsor:

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine

研究实施负责(组长)单位地址:

黑龙江省南岗区果戈里大街411号

Primary sponsor's address:

411 Gogol Street Nangang District Heilongjiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

黑龙江省

市(区县):

Country:

china

Province:

heilongjiang Province

City:

单位(医院):

黑龙江中医药大学

具体地址:

黑龙江省哈尔滨市和平路24号

Institution
hospital:

Heilongjiang University of Chinese Medicine

Address:

24 Heping Road Harbin City Heilongjiang Province

经费或物资来源:

任督二脉治疗胞宫和脑疾病的“体表-经络-脏腑相 关”规律研究

Source(s) of funding:

Research on the "Correlation between the Surface Meridians and Viscera" Law of Treating Uterine and Cerebral Diseases by Ren and Du Meridians

研究疾病:

缺血性中风后运动功能障碍

研究疾病代码:

Target disease:

Motor dysfunction after ischemic stroke

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

1.本课题旨在明确督脉针刺治疗IS后运动功能障碍的临床疗效及安全性; 2.基于功能磁共振成像技术,探究缺血性中风后运动功能障碍患者局部脑功能及脑网络的差异性改变,结合简化的(Fugl-Meyer Assessment, FMA)量表评价患者运动功能,应用Spearman检验,观察患者运动功能与大脑局部功能及脑区间功能连接度的相关性; 3.阐释督脉针刺介导的康复过程中大脑功能指标的特征性变化,及其与患者运动功能改变的相关性,为督脉针刺治疗IS后运动功能障碍提供科学依据。

Objectives of Study:

1. The purpose of this study IS to clarify the clinical efficacy and safety of acupuncture with the governor vein in the treatment of motor dysfunction after IS; 2. Based on functional magnetic resonance imaging the differential changes of local brain function and brain network in patients with motor dysfunction after ischemic stroke were explored and the motor function of patients was evaluated with simplified Fugl-Meyer Assessment (FMA) and Spearman test was applied. The correlation between motor function and local brain function and interbrain functional connectivity was observed. 3. To explain the characteristic changes of brain function indexes during rehabilitation mediated by governor vein acupuncture and their correlation with motor function changes of patients so as to provide scientific basis for the treatment of motor dysfunction after IS by governor vein acupuncture.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合西医及中医诊断标准且病程在2周以上,6个月以内属恢复期患者; (2)所有患者既往均无缺血性或出血性中风病史,此次为首次发病; (3)年龄40~75岁; (4)梗死病灶位于单侧运动通路上(单侧基底节和(或)放射冠区域); (5)患者血压稳定在160/100mmHg以下; (6)运动功能障碍与缺血性中风相关,缺血性中风前无其他疾病引起的运动功能障碍; (7)存在单侧肢体运动功能障碍(简易FMA评分<99分); (8)生命体征平稳,无语言功能及听力功能障碍,可配合治疗; (9)愿意接受本课题研究的治疗方案,自愿加入研究且签署知情同意书。 (10)所有患者均经爱丁堡利手量表判定为右利手; (11)患者病情相对平稳,能配合核磁扫描及临床信息采集; (12)近一月来未服用精神类药物; (13)无核磁检查禁忌症;

Inclusion criteria

(1) Patients who meet the diagnostic criteria of Western medicine and Chinese medicine and whose course of disease is more than 2 weeks and who are convalescent within 6 months; (2) All patients had no previous history of ischemic or hemorrhagic stroke and this was the first time. (3) Age 40-75 years old; (4) The infarct lesions were located on a unilateral motor pathway (unilateral basal ganglia and/or radiative crown area); (5) The patient's blood pressure was stable below 160/100mmHg;  (6) Motor dysfunction is associated with ischemic stroke and there is no motor dysfunction caused by other diseases before ischemic stroke; (7) Unilateral limb motor dysfunction (simple FMA score <99); (8) Stable vital signs no speech function and hearing dysfunction can be treated;  (9) Willing to accept the treatment plan of this research voluntarily join the study and sign the informed consent. (10) All patients were found to be right-handed by Edinburgh Handedness Scale; (11) The patient's condition is relatively stable and can cooperate with nuclear magnetic scanning and clinical information collection; (12) Have not taken psychotropic drugs in the past month; (13) No contraindications for magnetic test;

排除标准:

(1)既往有出血性中风及缺血性中风病史者; (2)合并心、肺、肝、胆、肾、胰腺、造血系统疾病和恶性肿瘤等严重原发性疾病; (3)依从性差或有严重失语、严重听力障碍、智力障碍、理解障碍等不能配合治疗方案的情况; (4)合并颅内动脉瘤、血管畸形或脑肿瘤; (5)严重脑功能减退性疾病患者; (6)血红蛋白低于100g/L血小板计数小于100×109/L或国际标准化比率(INR)大于1.5(不可逆),有无法纠正的出血因素; (7)合并严重脊柱变形等影响督脉针刺者; (8)存在核磁检查禁忌症,如体内有金属装置植入、幽闭恐惧症等; (9)在MRI扫描结果中发现严重的颅内解剖结构不对称或有明确病变者。

Exclusion criteria:

(1) Patients with a history of hemorrhagic stroke or ischemic stroke; (2) Complicated with serious primary diseases such as heart lung liver gallbladder kidney pancreas hematopoietic system diseases and malignant tumors; (3) Poor compliance or severe aphasia severe hearing impairment intellectual impairment understanding impairment etc. can not cooperate with the treatment program; (4) Complicated with intracranial aneurysm vascular malformation or brain tumor; (5) Patients with severe brain hypofunction diseases; (6) Hemoglobin less than 100g/L platelet count less than 100×109/L or international standardized ratio (INR) greater than 1.5 (irreversible) there are irremediable bleeding factors; (7) Patients with severe spinal deformation and other effects on the coronary artery acupuncture; (8) There are contraindications for nuclear magnetic examination such as metal device implantation in the body claustrophobia etc.; (9) Severe intracranial anatomical asymmetry or definite lesions were found in MRI scan results.

研究实施时间:

Study execute time:

From 2025-04-04

To      2025-09-30

征募观察对象时间:

Recruiting time:

From 2025-04-04

To      2025-09-30

干预措施:

Interventions:

组别:

督脉针刺组

样本量:

210

Group:

Du pulse acupuncture group

Sample size:

干预措施:

在常规针刺基础上针刺神庭、百会、风府、大椎

干预措施代码:

Intervention:

On the basis of routine acupuncture acupuncture Shenting Baihui Fengfu Dazhi

Intervention code:

组别:

常规针刺组

样本量:

210

Group:

Conventional acupuncture group

Sample size:

干预措施:

上肢功能障碍针刺肩髃、曲池、外关、合谷,下肢运动功能障碍针刺环跳、风市、阳陵泉、阴陵泉、足三里、解溪

干预措施代码:

Intervention:

For upper limb dysfunction, acupuncture was performed on jian 髃, quchi, Waiguan and Hegu. For lower limb motor dysfunction, acupuncture was performed on Huantiao, fengshi, yanglingquan, Yinlingquan, Zusanli and Jiexi

Intervention code:

样本总量 Total sample size : 420

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

黑龙江省

市(区县):

Country:

china

Province:

heilongjiang Province

City:

单位(医院):

黑龙江中医药大学附属第二医院

单位级别:

三甲

Institution/hospital:

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

改良Barthel 指数

指标类型:

次要指标

Outcome:

Modified Barthel Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

美国国立卫生研究院卒中量表

指标类型:

次要指标

Outcome:

National Institutes of Health Stroke Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

功能核磁

指标类型:

次要指标

Outcome:

fMRI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Fugl-Meyer肢体功能

指标类型:

主要指标

Outcome:

Fugl-Meyer Assessment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 40
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机对照及分配隐秘:用SPSS 27.0统计软件由一名专门负责人员随机生成随机数字,并随机生成分配序列。将分组情况和干预措施装进一个不透明信封,有专人保管。该人员不参与其他试验工作。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomized control and secret allocation: SPSS 27.0 statistical software is used to randomly generate random numbers by a dedicated person and randomly generate distribution sequences. Pack the grouping information and interventions into an opaque envelope that someone will keep. This person will not participate in other test work.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

网络平台:https://edc.bjmu.edu.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Network platform:https://edc.bjmu.edu.cn/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and an electronic data capture

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统